Drug Trial Radar · NCT01916382
Suitability of Nitisinone in Alkaptonuria 2
Last checked: Nov 19, 2026Latest source record: May 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Apr 2014
Primary completion
Feb 2016
Study completion Feb 2, 2020
Sponsor
- Lead sponsor
- University of LiverpoolAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a proposal to develop the orphan designated drug, nitisinone, for the treatment of a rare Mendelian disease, Alkaptonuria (AKU). Thanks to our existing successful fundamental and clinical research (cell models, animal models, natural history studies), we are now ready for this final stage of clinical development of nitisinone for AKU: a phase 3 clinical trial to prove efficacy. The results of DevelopAKUre will allow us to make the case to the European Medicines Agency for marketing authorisation of nitisinone for AKU, thereby contributing to the goal of the International Rare Diseases Research Consortium of developing 200 new therapies by 2020.
Conditions
- Alkaptonuria
Interventions
NitisinoneDrug
drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24 houre Urine Homogentisic acidTime frame: year 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Liverpool Hospital
Liverpool, Merseyside, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.